Seattle Genetics Inc SGEN:NASDAQ

Last Price$184.95NASDAQ Previous Close - Last Trade as of 3:59PM ET 9/25/20

Today's Change+5.52(3.08%)
Bid (Size)$184.00 (2)
Ask (Size)$184.74 (1)
Day Low / High$178.87 - 186.31
Volume859.0 K
 

View Biotechnology IndustryPeer Comparison as of 09/25/2020

 

Seattle Genetics Inc ( NASDAQ )

Price: $184.95
Change: +5.52 (3.08%)
Volume: 859.0 K
3:59PM ET 9/25/2020
 
 

Moderna Inc ( NASDAQ )

Price: $69.47
Change: +2.31 (3.44%)
Volume: 9.2 M
3:59PM ET 9/25/2020
 
 

Alexion Pharmaceuticals Inc ( NASDAQ )

Price: $114.43
Change: +2.00 (1.78%)
Volume: 1.8 M
4:00PM ET 9/25/2020
 
 

Biogen Inc ( NASDAQ )

Price: $273.28
Change: +3.24 (1.20%)
Volume: 737.5 K
4:00PM ET 9/25/2020
 
 

Illumina Inc ( NASDAQ )

Price: $299.89
Change: +13.58 (4.74%)
Volume: 4.3 M
4:00PM ET 9/25/2020
 

Read more news Recent News

Insider Trends: Seattle Genetics Insider Reports Option Conversion in Face of 90-Day Selling Trend
7:30PM ET 9/23/2020 MT Newswires

Jean I Liu, GC/EVP, Leg Affairs, exercised options for 9,954 shares in Seattle Genetics (SGEN) for $366,019 on Sep 21, 2020. Liu, following the...

Analysts' Ratchet Up Q3, 2020, 2021 Consensus Estimates for Seattle Genetics
1:05AM ET 9/23/2020 MT Newswires

Seattle Genetics Inc's (NASDAQ:SGEN, Recent Price: 181.95) forecasted earnings estimates for Q3 ending September 30, 2020, and the expectations for 2020...

Analyst Actions: Stifel Nicolaus Adjusts Seattle Genetics' Price Target to $165 From $145, Maintains Hold Rating
10:20AM ET 9/22/2020 MT Newswires

Seattle Genetics (SGEN) has an average rating of outperform and price targets ranging from $138 to $252, according to analysts polled by Capital IQ. (MT...

Analyst Actions: JMP Securities Adjusts Seattle Genetics' Price Target to $200 From $185, Maintains Market Outperform Rating
10:19AM ET 9/22/2020 MT Newswires

Seattle Genetics (SGEN) has an average rating of outperform and price targets ranging from $138 to $252, according to analysts polled by Capital IQ. (MT...

Company Profile

Business DescriptionSeattle Genetics, Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. View company web site for more details
Address21823-30th Drive SE
Bothell, Washington 98021
Phone+1.425.527.4000
Number of Employees1,302
Recent SEC Filing09/23/20204
Chairman, President & Chief Executive OfficerClay B. Siegall
Chief Financial OfficerTodd E. Simpson
Chief Technical OfficerVaughn B. Himes
Senior Vice President-Clinical DevelopmentRobert J. Lechleider

Company Highlights

Price Open$179.00
Previous Close$179.43
52 Week Range$72.27 - 187.99
Market Capitalization$32.2 B
Shares Outstanding174.0 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement11/03/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.50
Beta vs. S&P 500N/A
Revenue$654.7 M
Net Profit Margin-25.18%
Return on Equity-14.13%

Analyst Ratings as of 08/21/2020

Buy
12
Overweight
0
Hold
7
Underweight
1
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset